You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
|
|---|---|
| Published in |
BMC Pulmonary Medicine, May 2016
|
| DOI | 10.1186/s12890-016-0229-x |
| Pubmed ID | |
| Authors |
David S. Poch |
| Abstract |
We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications. A 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover high-dose sildenafil in addition to ERA therapy. This case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no interruption in therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 14% |
| Student > Postgraduate | 2 | 14% |
| Researcher | 2 | 14% |
| Student > Ph. D. Student | 1 | 7% |
| Student > Bachelor | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 5 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 21% |
| Medicine and Dentistry | 3 | 21% |
| Agricultural and Biological Sciences | 1 | 7% |
| Unknown | 7 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2016.
All research outputs
#14,851,946
of 22,873,031 outputs
Outputs from BMC Pulmonary Medicine
#964
of 1,923 outputs
Outputs of similar age
#198,463
of 334,245 outputs
Outputs of similar age from BMC Pulmonary Medicine
#19
of 40 outputs
Altmetric has tracked 22,873,031 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,923 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,245 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.